AU780011B2 - Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route - Google Patents
Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route Download PDFInfo
- Publication number
- AU780011B2 AU780011B2 AU72285/00A AU7228500A AU780011B2 AU 780011 B2 AU780011 B2 AU 780011B2 AU 72285/00 A AU72285/00 A AU 72285/00A AU 7228500 A AU7228500 A AU 7228500A AU 780011 B2 AU780011 B2 AU 780011B2
- Authority
- AU
- Australia
- Prior art keywords
- matrix tablet
- tablet according
- trimetazidine
- matrix
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
P/00/011 28/5/91 Regulation 32(2)
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: MATRIX TABLET ENABLING THE PROLONGED RELEASE OF TRIMETAZIDINE AFTER ADMINISTRATION BY THE ORAL ROUTE The following statement is a full description of this invention, including the best method of performing it known to us The present invention relates to a matrix tablet enabling the prolonged release of trimetazidine, or an addition salt thereof with a pharmaceutically acceptable acid, after administration by the oral route.
Trimetazidine, or 1-(2,3,4-trimethoxybenzyl)piperazine, is a compound which, by maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia, avoids the collapse of the intracellular level of adenosine triphosphate (ATP). It thus ensures functioning of the ion pumps and sodium-potassium transmembrane flows and maintains cellular homeostasis.
Trimetazidine dihydrochloride is currently used therapeutically for the prophylactic treatment of angina pectoris crisis, in chorioretinal attacks and for the treatment of vertigo of vascular origin (Mniere's vertigo, tinnitus).
Trimetazidine dihydrochloride has, until now, been administered by the oral route at doses of from 40 to 60 mg/day, in the form of tablets containing 20 mg of active ingredient or a drinkable solution containing 20 mg of active ingredient per ml. Those two forms are 15 immediate-release forms. Patent FR 2 490 963 describes the immediate-release tablet form.
Trimetazidine dihydrochloride is rapidly absorbed and eliminated by the body, its plasma half-life being less than 6 hours, which means that administration of the active ingredient has to be split into 2 or 3 administrations per day in order to ensure sufficient plasma levels. The dosage regimen most frequently required during treatments is three tablets per day. Multiple daily administrations bear the risk of being forgotten both by patients leading an active life and by elderly patients already taking a number of medications.
Because of the rapid absorption and the 6-hour half-life, such immediate-release forms result in low levels in the blood by the time of the next administration. It is known to be important to maintain effective myocardial protection throughout the 24-hour period and especially in the early morning when the consequences of ischaemia are most serious.
Because complete coverage of the day is not achieved with the immediate-release form, the Applicant has developed a prolonged-release form enabling perfect 24-hour coverage, ensuring a sufficient level in the blood between two administrations whilst retaining a large plasma peak after each administration so as to maintain the efficacy of the trimetazidine, maintaining the energy metabolism of a cell exposed to hypoxia or ischaemia and avoiding the lowering of the intracellular level of ATP.
It also allows peripheral vasodilator effects to be avoided, while stabilising blood flow rates and tensional effects.
The new formulation according to the invention accordingly allows the positive characteristics of the formulation described in patent FR 2 490 963 to be retained while enabling better coverage of the day, which leads to better compliance and permanent protection.
The present invention relates more especially to a matrix tablet which enables the prolonged release of trimetazidine, or a pharmaceutically acceptable salt thereof, after administration by the oral route and which is composed of a hydrophilic matrix characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.
15 This matrix tablet, administrable preferably twice a day, enables prolonged active ingredient release to be obtained whilst retaining a large plasma peak on each administration. It allows plasma levels greater than 70 plg/l to be obtained in humans after each administration and a plasma level greater than or equal to 40 pg/l to be maintained until the next administration, which was not the case with the tablet described in patent 20 FR 2 490 963 when administered 3 times per day.
Among the cellulose derivatives used in the matrix according to the invention, there may be mentioned, more especially, cellulose ethers such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, methylcellulose and hydroxypropyl methylcellulose.
The cellulose derivative is preferably hydroxypropyl methylcellulose. The percentage of cellulose derivative polymer is from 25 to 50 of the total mass of the tablet.
Hydroxypropyl methylcelluloses that have a viscosity of from 100 cP to 100 000 cP may be used. The preferred viscosity is 4 000 cP.
Various excipients are added to the hydrophilic matrix, for example binders, diluents, lubricants and flow agents. Among the binders, polyvidone is preferably used. The percentage of polyvidone is from 3 to 12 of the total mass of the tablet. Among the diluents, calcium hydrogen phosphate dihydrate is preferably used, which provides better fluidity and better compressibility than other diluents such as lactose monohydrate. The percentage of calcium hydrogen phosphate is from 25 to 75 of the total mass of the tablet.
Among the lubricants, there may be mentioned, without implying any limitation, magnesium stearate, stearic acid, glycerol behenate and sodium benzoate. The preferred lubricant is magnesium stearate. Finally, colloidal silica is preferably used as flow agent.
The trimetazidine used in the matrix tablets according to the invention is preferably in the dihydrochloride form.
The percentage of trimetazidine dihydrochloride is from 15 to 30 of the total mass of the tablet, preferably from 15 to 18 The person skilled in the art will generally consider the release kinetics of matrix tablets to be dependent on the nature and amount of the basic component of the matrix in this case, •namely, the cellulose derivative.
20 It now appears, surprisingly, that the release kinetics of the matrix tablet according to the invention are influenced neither by the amount nor by the grade of the cellulose derivative used.
Various formulations produced using, on the one hand, hydroxypropyl methylcelluloses of different viscosities and, on the other hand, variable amounts of the same grade of -4hydroxypropyl methylcellulose have exhibited equivalent release kinetics, which implies that there exists a specific synergy between the cellulose derivative and the trimetazidine.
The present invention relates also to a process for the preparation of the matrix tablet. The matrix tablet may be prepared by wet granulation followed by compression, by dry granulation followed by compression, or by direct compression. The preparation process is preferably wet granulation followed by compression.
The wet granulation is performed by mixing the trimetazidine, the polyvidone and the diluent, and then wetting that mixture. That first step enables a hydrophilic environment to be created around the active ingredient, which is beneficial for its dissolution, and also enables a unit dose that is as uniform as possible to be obtained.
In a second step, the previously obtained granulate is mixed with the cellulose derivative.
The lubricant and the flow agent are then added to the mixture. The third step is compression of the lubricated mixture previously obtained.
The tablets thus formed are then, if desired, coated according to a conventional coating o 15 technique.
The following Examples illustrate the invention but do not limit it in any way. The matrix tablets described in the Examples were prepared in the following manner S'.i Slep A Mixture of trimetazidine, polyvidone and calcium hydrogen phosphate dihydrate, •then wetting of the mixture using a sufficient amount of purified water, granulation and then drying of the granulate.
StepB Mixture of the granulate obtained in Step A with hydroxypropyl methylcellulose.
-StepC Lubrication of the mixture obtained in Step B with magnesium stearate and colloidal silica.
Step D Compression of the lubricated mixture obtained in Step C on a rotary tablet machine so as to obtain tablets having a hardness of about from 40 to 160 N, measured by breaking across a diameter.
EXAMPLE 1 Formulations of different matrix tablets containing various amounts of trimetazidine Table 1 Unitary formulae for 3 types of tablet Amount (mg) Compound FI F 2
F
3 Trimetazidine dihydrochloride 60 30 Hydroxypropyl methylcellulose 112 74 74 Polyvidone 13.3 8.7 8.7 Calcium hydrogen phosphate dihydrate 92 85.9 80.9 Magnesium stearate 2.2 1 1 Anhydrous colloidal silica 0.5 0.4 0.4 Total mass of the tablet 280 200 200 EXAMPLE 2 Example 2 shows that different amounts of hydroxypropyl methylcellulose influence on the dissolution kinetics of the tablet.
do not have an Table 2 Unitary formulae variable amounts of HPMC Compound Amount (mg)
F
4 Fs Trimetazidine dihydrochloride 35 Hydroxypropyl methylcellulose 54 94 Polyvidone 10.1 7.3 Calcium hydrogen phosphate dihydrate 99.5 62.3 Magnesium stearate 1 1 Anhydrous colloidal silica 0.4 0.4 Total mass of the tablet 200 200 -6- Table 3 shows the percentages of compound released as a function of time for the formulations F 4 and F 5 Table 3 Release kinetics Time Percentage of compound released Time
F
4 Fs 1 41 38 2 59 59 3 80 77 4 97 96 EXAMPLE 3: Example 3 shows that different grades of hydroxypropyl methylcellulose do not have an influence on the dissolution kinetics of the tablet.
Table 4 Formulations variable grades ofHPMC Amount (mg) Compound F3 F6 F7 Trimetazidine dihydrochloride 35 35 Hydroxypropyl methylcellulose 4000 cP 74 Hydroxypropyl methylcellulose 100 cP 74 Hydroxypropyl methylcellulose 100 000 cP 74 Polyvidone 8.7 8.7 8.7 Calcium hydrogen phosphate dihydrate 80.9 80.9 80.9 Magnesium stearate 1 1 1 Anhydrous colloidal silica 0.4 0.4 0.4 Table 5 shows the percentages of compound released as a function of time for the formulations F 3
F
6 and F 7 Table 5 Release kinetics Time Percentage of compound released
F
3 i F 6
F
7 1 43 41 2 62 59 3 86 83 83 4 105 102 100 -7- EXAMPLE 4 Plasma kinetics study The plasma kinetics were studied after administration of the matrix tablet of formulation F 3 described in Example 1 to 12 healthy volunteers.
Administration was carried out for 4 days at the rate of two tablets per day.
The plasma kinetics of the tablet of formula F 3 were compared to those of an immediaterelease (IR) tablet administered for 4 days at the rate of three tablets per day.
The unitary formulation of the immediate-release (IR) tablet is as follows Trimetazidine dihydrochloride 20 mg M aize 26 m g M ann ito l 34 m g Polyvidone 4 m g Magnesium stearate 1 mg T alc 5 m g 15 The average plasma concentration is given in Figure 1.
8 Figure I Plasma kinetics of trimetazidine Average plasma concentrations of trimetazidine (in pg/l) after oral administration of the F 3 form and an IR form to 12 healthy volunteers Plasma concentration
IR
100-
F
3 1\ 040- 15 0 .II .i i Time (h) 0 73 75 77 79 82 85 87 90 96 S" This curve clearly shows that the F 3 form enables prolonged release of trimetazidine to be 20 obtained while retaining a large plasma peak on each administration.
The plasma level observed after each administration is close to 90 pg/l and hardly different from that obtained with the IR form. At the end of 24 hours the plasma level is greater than pg/I whereas, with the immediate-release formulation, it is only about 25 pg/1.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (20)
1- Matrix tablet for the prolonged release of trimetazidine or a pharmaceutically acceptable salt thereof, characterised in that the prolonged release is controlled by the use of a cellulose derivative polymer.
2- Matrix tablet according to claim 1, characterised in that the cellulose derivative polymer is a hydroxypropyl methylcellulose.
3- Matrix tablet according to either claim 1 or claim 2, characterised in that the percentage of cellulose derivative is from 25 to 50 of the total mass of the tablet.
4- Matrix tablet according to claim 1, characterised in that it also comprises a binder, a 10 diluent, a lubricant and a flow agent.
5- Matrix tablet according to claim 4, characterised in that the binder is polyvidone. p*
6- Matrix tablet according to claim 5, characterised in that the percentage of polyvidone is from 3 to 12 of the total mass of the tablet.
7- Matrix tablet according to any one of claims 4, 5 or 6, characterised in that the diluent is S 15 calcium hydrogen phosphate dihydrate.
8- Matrix tablet according to claim 7, characterised in that the percentage of calcium hydrogen phosphate dihydrate is from 25 to 75 of the total mass of the tablet.
9- Matrix tablet according to any one of claims 4, 5, 6, 7 or 8, characterised in that the lubricant is magnesium stearate and the flow agent is anhydrous colloidal silica.
Matrix tablet according to claim 1, characterised in that the trimetazidine is in the dihydrochloride form.
11. Matrix tablet according to claim 10, characterised in that the percentage of trimetazidine dihydrochloride is from 15 to 30% of the total mass of the tablet.
12. Matrix tablet according to either claim 10 or claim 11, characterised in that the percentage of trimetazidine dihydrochloride is 17.5% of the total mass of the tablet.
13. Matrix tablet according to any one of claims 1 to 12, characterised in that it contains 35 mg of trimetazidine dihydrochloride, 74 mg of hydroxypropyl 10 methylcellulose, 8.7 gm of polyvidone, 80.9 mg of calcium hydrogen phosphate dihydrate, 1 mg of magnesium stearate and 0.4 mg of anhydrous colloidal silica.
14. Matrix tablet according to claim 13, characterised in that it is administered twice per day. S
15. Matrix tablet according to claim 1, characterised in that it enables plasma levels greater than 70 gg/I to be obtained in humans after each administration and a plasma level greater than or equal to 40 jg/I to be maintained until the next administration.
16. Process for the preparation of a matrix tablet according to any one of claims 1 to 13, characterised in that: wet granulation is carried out by mixing trimetazidine, polyvidone and the diluent and then wetting that mixture, the granulate thus obtained is mixed with the cellulose derivative, the lubricant and the flow agent are then added, the previous mixture is then compressed. 11
17. Matrix tablet according to any one of claims 1 to 15 for use in the prophylactic treatment of angina pectoris, in chorioretinal attacks and in the treatment of vertigo of vascular origin.
18. A method of treatment or prophylaxis of angina pectoris in chorioretinal attacks and vertigo of vascular origin, which method comprises administration of a matrix tablet according to any one of claims 1 to
19. A matrix tablet substantially as hereinbefore described with reference to Example 1 or Example 2. 10
20. A process for preparation of a matrix tablet substantially as hereinbefore described. DATED this 6th day of December 2004 LES LABORATOIRES SERVIER WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P18738AU00 CJH/RNE/VRH
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9915960 | 1999-12-17 | ||
| FR9915960A FR2802424B1 (en) | 1999-12-17 | 1999-12-17 | MATRIX TABLET FOR THE EXTENDED RELEASE OF TRIMETAZIDINE AFTER ORAL ADMINISTRATION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7228500A AU7228500A (en) | 2001-06-21 |
| AU780011B2 true AU780011B2 (en) | 2005-02-24 |
Family
ID=9553398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU72285/00A Expired AU780011B2 (en) | 1999-12-17 | 2000-12-14 | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1108424B2 (en) |
| JP (2) | JP2001172181A (en) |
| KR (1) | KR100456933B1 (en) |
| CN (1) | CN1166408C (en) |
| AR (1) | AR026968A1 (en) |
| AT (1) | ATE296622T1 (en) |
| AU (1) | AU780011B2 (en) |
| BG (1) | BG65773B1 (en) |
| BR (1) | BR0005915A (en) |
| CY (1) | CY2347B1 (en) |
| CZ (1) | CZ299461B6 (en) |
| DE (1) | DE60020501T3 (en) |
| DK (1) | DK1108424T4 (en) |
| EA (2) | EA200501901A1 (en) |
| ES (2) | ES2176106B1 (en) |
| FR (1) | FR2802424B1 (en) |
| GE (1) | GEP20053540B (en) |
| GR (1) | GR1003658B (en) |
| HK (1) | HK1036937A1 (en) |
| HU (1) | HU226956B1 (en) |
| IE (1) | IE20001017A1 (en) |
| IT (1) | IT1317075B1 (en) |
| LU (1) | LU90700B1 (en) |
| MX (1) | MXPA00012462A (en) |
| NZ (1) | NZ508912A (en) |
| OA (1) | OA12121A (en) |
| PL (1) | PL206994B1 (en) |
| PT (2) | PT102542A (en) |
| SI (1) | SI1108424T2 (en) |
| SK (1) | SK286752B6 (en) |
| UA (1) | UA80087C2 (en) |
| WO (1) | WO2001043747A1 (en) |
| ZA (1) | ZA200007548B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009034541A3 (en) * | 2007-09-11 | 2009-07-30 | Ranbaxy Lab Ltd | Controlled release pharmaceutical dosage forms of trimetazidine |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1195160E (en) * | 2000-10-05 | 2009-12-07 | Usv Ltd | Sustained release trimetazidine pharmaceutical compositions and a method of their preparation |
| US20070092566A1 (en) | 2003-08-04 | 2007-04-26 | Ryouichi Hoshino | Oral sustained-release tablet |
| SG126792A1 (en) * | 2005-04-27 | 2006-11-29 | Servier Lab | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route |
| FR2885807B1 (en) * | 2005-05-18 | 2008-05-16 | Mg Pharma | SOLID PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF 1- (2,3,4-TRIMETHOXYBENZYL) PIPERAZINE, AND PREPARATION METHOD |
| CZ300307B6 (en) * | 2006-01-04 | 2009-04-15 | Zentiva, A. S. | Modified release tablet containing trimetazidine or pharmacologically acceptable salts thereof |
| EA009776B1 (en) * | 2006-07-18 | 2008-04-28 | Мераб Ревазович Кокеладзе | Method for preparing tablets of dihydrochloride trimethazine and composition thereof |
| EA009810B1 (en) * | 2006-12-26 | 2008-04-28 | Закрытое Акционерное Общество "Канонфарма Продакшн" | Matrix for manufacturing tableted dosage form and method of treatment |
| EP2389167A2 (en) | 2009-01-20 | 2011-11-30 | Micro Labs Limited | Modified release solid pharmaceutical compositions of trimetazidine and process thereof |
| ES2567722T3 (en) * | 2009-01-30 | 2016-04-26 | Lupin Limited | Trimetazidine pharmaceutical compositions |
| TR201001902A2 (en) | 2010-03-12 | 2011-04-21 | Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Trimetazidine tablets with extended release |
| RU2445958C2 (en) * | 2010-04-20 | 2012-03-27 | Общество с ограниченной ответственностью "Озон" (ООО "Озон") | Matrix tablet with trimetazidine prolonged-release base and method for preparing it |
| ES2508490T3 (en) | 2010-05-04 | 2014-10-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Formulation of trimetazidine with different release profiles |
| EP2386302A1 (en) | 2010-05-11 | 2011-11-16 | Ranbaxy Laboratories Limited | A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof |
| EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| FR2978916B1 (en) * | 2011-08-10 | 2013-07-26 | Servier Lab | SOLID PHARMACEUTICAL COMPOSITION FOR BUCCAL ADMINISTRATION OF AGOMELATIN |
| FR2986431B1 (en) * | 2012-02-03 | 2017-03-17 | Servier Lab | PROLONGED RELEASE OF TRIMETAZIDINE PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PRODUCTION THEREOF AND USE IN THERAPEUTIC TREATMENTS |
| CN102824644B (en) * | 2012-09-13 | 2013-12-25 | 浙江诚意药业有限公司 | High-stability sustained-release tablet prepared by using hydroxy propyl cellulose |
| KR20160118733A (en) | 2015-04-03 | 2016-10-12 | 이인현 | Hose guide apparatus for hose winder and hose winder |
| CN109316455B (en) * | 2017-07-31 | 2021-05-25 | 北京福元医药股份有限公司 | Trimetazidine hydrochloride sustained release tablet |
| CN109908096A (en) * | 2017-12-12 | 2019-06-21 | 武汉武药科技有限公司 | A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
| FR2490963B1 (en) * | 1980-09-30 | 1986-04-18 | Science Union & Cie | NOVEL THERAPEUTIC COMPOSITION WITH ANTI-ISCHEMIC ACTION CONTAINING TRIMETHOXY 2, 3, 4-BENZYL 1-PIPERAZINE |
| KR850006132A (en) * | 1984-02-29 | 1985-10-02 | 진 크라메르, 한스 루돌프 하우스 | Bromocriptine Composition |
| JPS61293931A (en) * | 1985-06-24 | 1986-12-24 | Teijin Ltd | Slow-releasing pharmaceutical composition |
| JPH0625055B2 (en) * | 1985-03-18 | 1994-04-06 | 日本ケミフア株式会社 | Persistent tablets |
| EP0207638B1 (en) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Sustained-release pharmaceutical preparation |
| SE455836B (en) * | 1985-10-11 | 1988-08-15 | Haessle Ab | PREPARATION WITH CONTROLLED RELEASE CONTAINING A SALT OF METOPROLOL AND METHOD FOR PREPARING THIS PREPARATION |
| SE8601624D0 (en) * | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
| FR2677886B1 (en) * | 1991-06-18 | 1995-03-31 | Adir | MATRIX TABLET FOR THE EXTENDED RELEASE OF INDAPAMIDE AFTER ORAL ADMINISTRATION. |
| FR2681324B1 (en) * | 1991-09-18 | 1993-10-29 | Adir Cie | NOVEL TRIMETAZIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| KR940021051A (en) * | 1993-03-03 | 1994-10-17 | 손정삼 | 3-step drug release sustained tablet |
| RU2082400C1 (en) * | 1993-12-16 | 1997-06-27 | Акционерное общество - Фармацевтическая фирма "Ник-Фарм" | Method of nitroglycerol prolonged action preparing |
| FR2717687B1 (en) * | 1994-03-24 | 1996-06-14 | Adir | Pharmaceutical compositions for the sustained release of trimetazidine after oral administration. |
-
1999
- 1999-12-17 FR FR9915960A patent/FR2802424B1/en not_active Expired - Fee Related
-
2000
- 2000-12-11 JP JP2000375812A patent/JP2001172181A/en active Pending
- 2000-12-14 IT IT2000RM000667A patent/IT1317075B1/en active
- 2000-12-14 CY CY0000059A patent/CY2347B1/en unknown
- 2000-12-14 MX MXPA00012462A patent/MXPA00012462A/en active IP Right Grant
- 2000-12-14 AU AU72285/00A patent/AU780011B2/en not_active Expired
- 2000-12-15 EP EP00403533.3A patent/EP1108424B2/en not_active Expired - Lifetime
- 2000-12-15 ES ES200003018A patent/ES2176106B1/en not_active Expired - Fee Related
- 2000-12-15 SK SK863-2002A patent/SK286752B6/en not_active IP Right Cessation
- 2000-12-15 DK DK00403533.3T patent/DK1108424T4/en active
- 2000-12-15 IE IE20001017A patent/IE20001017A1/en not_active Application Discontinuation
- 2000-12-15 LU LU90700A patent/LU90700B1/en active
- 2000-12-15 PT PT102542A patent/PT102542A/en not_active IP Right Cessation
- 2000-12-15 GR GR20000100433A patent/GR1003658B/en unknown
- 2000-12-15 KR KR10-2000-0076962A patent/KR100456933B1/en active IP Right Review Request
- 2000-12-15 CN CNB001380605A patent/CN1166408C/en not_active Expired - Lifetime
- 2000-12-15 ES ES00403533.3T patent/ES2240033T5/en not_active Expired - Lifetime
- 2000-12-15 OA OA1200200181A patent/OA12121A/en unknown
- 2000-12-15 PL PL344564A patent/PL206994B1/en not_active IP Right Cessation
- 2000-12-15 CZ CZ20022082A patent/CZ299461B6/en not_active IP Right Cessation
- 2000-12-15 GE GE4838A patent/GEP20053540B/en unknown
- 2000-12-15 AT AT00403533T patent/ATE296622T1/en active
- 2000-12-15 NZ NZ508912A patent/NZ508912A/en not_active IP Right Cessation
- 2000-12-15 UA UA2002075914A patent/UA80087C2/en unknown
- 2000-12-15 PT PT00403533T patent/PT1108424E/en unknown
- 2000-12-15 WO PCT/FR2000/003546 patent/WO2001043747A1/en active IP Right Grant
- 2000-12-15 SI SI200030704T patent/SI1108424T2/en unknown
- 2000-12-15 AR ARP000106662A patent/AR026968A1/en not_active Application Discontinuation
- 2000-12-15 HU HU0004966A patent/HU226956B1/en active IP Right Maintenance
- 2000-12-15 DE DE60020501.0T patent/DE60020501T3/en not_active Expired - Lifetime
- 2000-12-15 ZA ZA200007548A patent/ZA200007548B/en unknown
- 2000-12-18 EA EA200501901A patent/EA200501901A1/en unknown
- 2000-12-18 BR BR0005915-3A patent/BR0005915A/en not_active Application Discontinuation
- 2000-12-18 EA EA200001201A patent/EA008223B1/en not_active IP Right Cessation
-
2001
- 2001-11-12 HK HK01107928A patent/HK1036937A1/en not_active IP Right Cessation
-
2002
- 2002-07-16 BG BG106927A patent/BG65773B1/en unknown
-
2007
- 2007-08-31 JP JP2007224959A patent/JP2007314578A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009034541A3 (en) * | 2007-09-11 | 2009-07-30 | Ranbaxy Lab Ltd | Controlled release pharmaceutical dosage forms of trimetazidine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU780011B2 (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
| AU705488B2 (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| CA2289260C (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| JP4172820B2 (en) | Fast-dissolving galantamine hydrobromide tablets | |
| EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
| AU2001260212A1 (en) | Composition | |
| CA1272957A (en) | Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine | |
| JPH0757726B2 (en) | Sustained release tablets based on high molecular weight hydroxypropyl methylcellulose | |
| EP1171134A1 (en) | Controlled release of sildenafil delivered by sublingual or buccal administration | |
| WO2020148217A1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| KR20090104785A (en) | Stable extended release oral dosage composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: LES LABORATOIRES SERVIER Free format text: THE FORMER OWNER WAS: ADIR ET COMPAGNIE |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |